UroGen Pharma
URGN
82 hedge funds and large institutions have $214M invested in UroGen Pharma in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 14 closing their positions.
2% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.31M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.46% less ownership
Funds ownership: 64.21% → 62.75% (-1.5%)
8% less funds holding
Funds holding: 89 → 82 (-7)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
23% less capital invested
Capital invested by funds: $277M → $214M (-$63.5M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$3.72M |
| 2 |
Morgan Stanley
New York
|
+$1.31M |
| 3 |
BlackRock
New York
|
+$1.02M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.02M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$913K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.79M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$4.35M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.53M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$817K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$768K |
URGN Hedge Fund Activity: Q2 2021 in Review
82 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2021, worth a combined $214M — down 23% from $277M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of URGN and 7 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 24 added.
The largest buyer was Zeke Capital Advisors, adding an estimated $3.72M. The largest seller was Wellington Management Group, cutting an estimated $4.79M.
- 82 institutional investors held UroGen Pharma (URGN) as of Q2 2021, down from 89 in Q1 2021.
- Funds reported $214M of UroGen Pharma stock for Q2 2021, down 23% quarter-over-quarter.
- 7 funds opened new UroGen Pharma positions in Q2 2021 and 14 closed out, a net change of -7 holders.
- The largest UroGen Pharma buyer in Q2 2021 was Zeke Capital Advisors, an estimated $3.72M added.
- The largest UroGen Pharma seller in Q2 2021 was Wellington Management Group, an estimated $4.79M sold.
Based on aggregated 13F filings for Q2 2021.